Teva Pharmaceutical Industries’ (TEVA) fourth
quarter earnings of $1.59 per American Depository Share (ADS) were
a penny above the Zacks Consensus Estimate and 27.2% above the
year-ago earnings.
Fourth quarter revenues increased 28.5% to $5.7 billion, just
above the Zacks Consensus Estimate of $5.6 billion.
Full year earnings increased 9.5% to $4.97 per share, in line
with the Zacks Consensus Estimate. Revenues increased 13.6% to
$18.3 billion, in line with the Zacks Consensus Estimate.
The Quarter in Detail
The company reported sales growth in RoW (44%), the US (32%) and
Europe (13%). Currency fluctuations negatively impacted total
revenues by $29 million.
Sales in the US grew 32% to $3 billion in the reported quarter,
boosted by the inclusion of Cephalon and the strong performance of
branded products.
Although US generic sales declined 5% to $1.2 billion, it showed
signs of reviving during the quarter with sales benefiting from the
exclusive generic launch of Eli Lilly’s (LLY)
Zyprexa. Teva has partnered with Dr. Reddy’s
Laboratories (RDY) for Zyprexa. Another important product
launch was that of a generic version of Pfizer’s
(PFE) Lipitor. Teva has an agreement with Ranbaxy regarding generic
Lipitor. Teva also launched a generic version of Combivir.
The performance of the US generics segment should continue
improving – the company expects $650 million in new launches in
2012 including more than $20 million from the launch of its generic
version of Forest Labs’ (FRX)
Lexapro. The company is guiding towards US generics segment sales
of $5 billion, with sales slated to benefit from patent expirations
and product launches. However, competition in the generics market
will be tough.
Branded product revenues increased 68% to $2.3 billion in the
fourth quarter. Revenues benefited from the inclusion of Cephalon
products – Provigil ($350 million), Treanda ($131 million) and
Nuvigil ($86 million). Oncology product, Treanda, is expected to
generate sales of $550 million in 2012. Sleep disorder drugs
Provigil and Nuvigil are expected to generate sales of $375 million
and $300 million, respectively, in 2012.
Key branded product Copaxone posted global in-market sales of $1
billion, up 8%. Copaxone sales are slated to exceed $3.8 billion in
2012.
Other products/segments that contributed to growth were Azilect
at $109 million, up 22%, and the global respiratory business ($275
million, up 27.3%). The women’s health business, however, recorded
a decline with sales coming in at $93 million (down 4.1%).
While Women’s Health products are expected to contribute $525
million to revenues, ProAir HFA is expected to generate revenues of
$490 million in 2012. QVAR and Azilect are slated to post revenues
of $400 million and $350 million, respectively, in 2012.
Total branded products are expected to contribute $8.2 billion
to the top line in 2012.
Revenues in Europe increased 13% to $1.5 billion. Results
benefited from the inclusion of ratiopharm’s business. Teva’s
acquisition of ratiopharm has helped the company strengthen its
position in key European markets, especially Germany. Strong
performance especially in Italy and Spain drove revenues.
RoW (Rest of the World including Canada, Israel, certain markets
in Eastern Europe, Latin America and Asia) revenues grew 44% during
the quarter with sales coming in at $1.1 billion. Increased sales
in Russia, Israel and certain parts of Latin America helped boost
revenues. Moreover, sales benefited from the July 2011 Taiyo
acquisition in Japan.
API sales increased 12% to $197 million. OTC revenues increased
19% to $217 million. OTC sales are expected to be about $1 billion
in 2012. Teva has a partnership agreement with Procter
& Gamble (PG) targeting the consumer health care
market.
Research & Development expense increased to $371 million
from $270 million in the year-ago period. The inclusion of Cephalon
was the main reason for the increase. Teva expects to spend between
6.9% to $7.3% of net sales on R&D in 2012. With the Cephalon
acquisition, Teva now has 40 late stage clinical programs, most of
which are in phase III. We expect detailed information on the
company’s innovative pipeline in mid-2012.
Meanwhile, Selling and Marketing (S&M) expenditures
increased to $1 billion from $816 million mainly due to the
inclusion of Cephalon, Taiyo and Theramex. Selling & marketing
expenses (including royalties of about $400 million) are expected
to range between 18.4% and 20% of net sales in 2012.
The company repurchased 3.7 million shares during the quarter.
Teva has a $3 billion share buyback program which was announced in
Dec 2011. We are positive on this program which will return value
to shareholders. We were also encouraged to hear that Teva
increased its annual dividend by 25%.
2012 Guidance Maintained
The company maintained its outlook for 2012 that was provided in
Dec 2011. The company expects to earn $5.48 and $5.68 per share on
total net sales of about $22 billion. The Cephalon
acquisition is expected to boost 2012 earnings by 20-25 cents. The
2012 Zacks Consensus Estimate currently stands at $5.59 per
share.
Our Take
We currently have a Neutral recommendation on Teva, which
carries a Zacks #3 Rank (short-term Hold rating). Teva ended 2011
on a strong note with the US generics business showing signs of
reviving. The increase in dividend is also encouraging. However,
the Copaxone patent case remains an overhang. We believe Teva will
pursue small deals and acquisitions to reduce its dependence on
Copaxone.
FOREST LABS A (FRX): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
PROCTER & GAMBL (PG): Free Stock Analysis Report
DOCTOR REDDYS (RDY): Free Stock Analysis Report
TEVA PHARM ADR (TEVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Apr 2024 to May 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2023 to May 2024